At RS Oncology we are working to give patients their best chance at surviving cancer. Our innovative approaches disrupt the chaos of aggressive cancers through a novel scientific mechanism. We are committed to every patient and their loved ones.
Motivated to provide new treatment options for patients, we are leveraging new scientific discoveries to develop meaningful therapies against the most aggressive cancers. Our team of drug developers, researchers, scientists, and doctors are focusing on cancers with limited treatment options, including rare and late-stage metastatic cancers.
Learn MoreRS Oncology is harnessing the metabolic vulnerability of cancer cells, by targeting the novel mitochondrial oncology target PRX3. We have successfully completed a Phase 1 clinical trial with a mitochondrial target in oncology.
Our PipelineRS Oncology is currently evaluating RSO-021 in a Phase 2 clinical trial in mesothelioma, metastatic breast cancer, metastatic ovarian cancer, and non-small cell lung cancer.
Learn More About Our Clinical TrialPhase I/II trial (MITOPE) demonstrates impressive disease control and overall survival with a favorable safety profile when patients were treated at the 90 mg dose level.
Read the announcement →